Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Horus Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Horus Pharma Becomes Additional Commercialization Partner for Formycon's Eylea Biosimilar
Details : The partnership aims for the commercialization of Formycon's Eylea biosimilar FYB203, under the brand name Baiama, in selected European countries.
Product Name : Baiama
Product Type : Protein
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Horus Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : FYB201
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ocular Safety and Usability Study for FYB201 PFS
Details : FYB201 is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : FYB201
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FYB203
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ocular Safety and Usability Study for FYB203 PFS
Details : FYB203 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : FYB203
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FYB206 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Fresenius SE & Co. KGaA
Deal Size : Inapplicable
Deal Type : Inapplicable
Fresenius & Formycon Receive U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)
Details : Otulfi (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.
Product Name : Otulfi
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Fresenius SE & Co. KGaA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FYB206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Fresenius Kabi AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar
Details : FYB202 (ustekinumab biosimilar) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin 23 for treatment of immune-mediated disorders.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 07, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Fresenius Kabi AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : ATHOS
Deal Size : $720.7 million
Deal Type : Acquisition
Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : ATHOS
Deal Size : $720.7 million
Deal Type : Acquisition
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : ATHOS
Deal Size : $720.7 million
Deal Type : Acquisition
Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
March 29, 2022
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : ATHOS
Deal Size : $720.7 million
Deal Type : Acquisition
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Bioeq IP AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive lo...
Product Name : Cimerli
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 06, 2021
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Bioeq IP AG
Deal Size : Inapplicable
Deal Type : Inapplicable